Bing Zhang, Ph.D.
Professor
Positions
- Professor
-
Lester and Sue Smith Breast Center
糖心视频 of Medicine
Houston, TX, US
- Professor
-
Department of Molecular and Human Genetics
糖心视频 of Medicine
- Member
-
Dan L Duncan Comprehensive Cancer Center
糖心视频 of Medicine
Houston, Texas, United States
- McNair Scholar
-
糖心视频 of Medicine
Houston, Texas, United States
- Faculty Member
-
Graduate Program in Quantitative and Computational Biosciences
糖心视频 of Medicine
- Faculty Member
-
Graduate Program in Cancer and Cell Biology
糖心视频 of Medicine
Addresses
- BCM-Jewish Building (Office)
-
Room: 648D
Houston, TX, 77030
United States
Phone: (713) 798-1443
bing.zhang@bcm.edu
Education
- BS from Nanjing University
- Nanjing, China
- PhD from Chinese Academy of Sciences
- Shanghai, China
- Postdoctoral Training at Oak Ridge National Laboratory
- Oak Ridge, Tennessee, United States
Honors & Awards
- CPRIT Scholar in Cancer Research
- Cancer Prevention Research Institute of Texas (09/2016)
- McNair Scholar
- McNair Medical Institute (08/2016)
- Gilbert S. Omenn Computational Proteomics Award
- US Human Proteome Organization (03/2023)
- Michael E. DeBakey Excellence in Research Award
- 糖心视频 of Medicine (05/2024)
Professional Interests
- Bioinformatics
- Systems biology
- Precision oncology
Professional Statement
My research interests encompass the broad areas of bioinformatics, computational proteomics, proteogenomics and cancer systems biology. During the past decade, through support from the National Cancer Institute鈥檚 Clinical Proteomic Tumor Analysis Consortium (CPTAC), I have established an internationally recognized research program in computational cancer proteogenomics, focusing on integrating genomic and proteomic data to better understand cancer biology and to improve cancer diagnosis and treatment. My group led the first integrative proteogenomic characterization of human cancer in a colorectal cancer cohort, which was published in Nature in 2014. The proteogenomics approach has now been applied to more than 10 cancer types within and outside CPTAC. My group participated in fourteen proteogenomics studies published in Nature, Cell and Cancer Cell. Together, these studies have demonstrated that integrated proteogenomic analysis provides functional context to interpret genomic abnormalities and that proteogenomics holds great potential to enable new advances in cancer biology, diagnosis, prognosis and targeted and immunotherapies.
To facilitate omics and multi-omics data analysis, my group has developed multiple widely used bioinformatics tools. CustomProDB is one of the first computational proteogenomics tools, and its expansion into NeoFlow enables proteogenomics-based neoantigen prioritization. The pathway and network analysis tool WebGestalt has been serving the biology research community for 17 years. In 2021 alone, WebGestalt was used >160,000 times by >56,000 users and was cited in >900 papers. The LinkedOmics web application makes multi-omics data from CPTAC and TCGA directly available and useful to the cancer research community. Published in 2018, the tool has already been used >150,000 times by >57,000 users, with >1000 citations.
Cancer proteogenomics is becoming a 鈥渄ata-rich鈥 field. My team will continue developing bioinformatics methods and tools to expedite the extraction of novel biological and clinical insights from the continually growing volume of data. We are also working actively with clinical collaborators to translate data-driven computational discoveries into treatment advances for patients.
To facilitate omics and multi-omics data analysis, my group has developed multiple widely used bioinformatics tools. CustomProDB is one of the first computational proteogenomics tools, and its expansion into NeoFlow enables proteogenomics-based neoantigen prioritization. The pathway and network analysis tool WebGestalt has been serving the biology research community for 17 years. In 2021 alone, WebGestalt was used >160,000 times by >56,000 users and was cited in >900 papers. The LinkedOmics web application makes multi-omics data from CPTAC and TCGA directly available and useful to the cancer research community. Published in 2018, the tool has already been used >150,000 times by >57,000 users, with >1000 citations.
Cancer proteogenomics is becoming a 鈥渄ata-rich鈥 field. My team will continue developing bioinformatics methods and tools to expedite the extraction of novel biological and clinical insights from the continually growing volume of data. We are also working actively with clinical collaborators to translate data-driven computational discoveries into treatment advances for patients.
Websites
Selected Publications
-
Wen B, Wang C, Li K, Han P, Holt MV, Savage SR, Lei JT, Dou Y, Shi Z, Li Y, Zhang B.. " " Nat Methods.. 2025 ;
Pubmed PMID: . -
Shi Z, Lei JT, Elizarraras JM, Zhang B. " " Nat Cancer.. 2025 ; 6 (1) : 205-222.
Pubmed PMID: . -
Savage SR, Yi X, Lei JT, Wen B, Zhao H, Liao Y, Jaehnig EJ, Somes LK, Shafer PW, Lee TD, Fu Z, Dou Y, Shi Z, Gao D, Hoyos V, Gao Q, Zhang B.. " " Cell.. 2024 ; 187 (16)
Pubmed PMID: . -
Vasaikar S, Huang C, Wang X, Petyuk VA, Savage SR, Wen B, Dou Y, Zhang Y, Shi Z, Arshad OA, Gritsenko MA, Zimmerman LJ, McDermott JE, 鈥... Ellis M, Thiagarajan M, Kinsinger CR, Rodriguez H, Smith RD, Rodland KD, Liebler DC, Liu T, Zhang B, CPTAC. " " Cell. 2019 ; 177 : 1035-1049.
Pubmed PMID: .
Funding
-
IPGDAC, an integrative proteogenomic data analysis center for CPTAC
- NIH/NCI
-
Proteogenomics-driven therapeutic discovery in hepatocellular carcinoma
- NIH/NCI
-
Signaling network modeling to identify new treatments for triple-negative breast cancer
- CPRIT
-
Advancing Protein Isoform Analysis through an Integrated Computational Framework
- NIH/NCI
-
Charting TCR- Tumor Antigen Interactions to Foster Novel Immunotherapeutic Approaches for Triple-Negative Breast Cancer
- CPRIT
-
Targeting Cryptic Splicing-Derived Neoantigens in hnRNPM-Dysregulated Triple-Negative Breast Cancer
- DOD
-
mRNA-based immunotherapy for targeting triple-negative breast cancer
- V Foundation
to edit your profile